Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 185 EUR
  • 25 mg - 745 EUR
  • 100 mg - 2220 EUR

Ruxolitinib

Ruxolitinib is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). It inhibits the proliferation of JAK2V617F-positive cells. In a mouse model of JAK2V617F-positive MPN, it markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells. This significantly increased survival without myelo- or immunosuppression.

catalogue number: R106
synonyms: INCB018424
CAS: 941678-49-5
MW: 306.37 g/mol

References
Org Lett. 2009 May 7;11(9):1999-2002. PMID: 19385672
Blood. 2010 Apr 15;115(15):3109-17. PMID: 20130243
J Immunol. 2010 May 1;184(9):5298-307. PMID: 20363976